Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina.
Location: United States, Texas, Austin
Employees: 51-200
Total raised: $118M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| - | Takeda Ven... | takeda.com |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Rocky Poin... | rockypoint... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.06.2020 | Series B | $118M | - |
Mentions in press and media 6
| Date | Title | Description |
| 29.02.2024 | Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights | - Announced positive topline data from the ongoing Phase 1A/B clinical trial of SL-172154 in combination with azacitidine (AZA) in frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and frontline TP53 mutant (TP53m) Acute Myeloid Leuk... |
| 10.01.2022 | Shattuck Labs : Corporate Presentation, January 10, 2022 | Corporate Overview NASDAQ: STTK January 10, 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial ris... |
| 11.08.2021 | Shattuck Labs : Corporate Presentation, August 11, 2021 | Corporate Overview NASDAQ: STTK August 11, 2021 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the federal securities laws, which statements are subject to substantial risk... |
| 15.06.2020 | Shattuck Labs Announces $118M Series B | DURHAM, NC, Shattuck Labs announced the closing of a $118 million Series B equity financing. >> Click here for more funding data on Shattuck Labs >> To export Shattuck Labs funding data to PDF and Excel, click here Shattu... |
| 15.06.2020 | Austin biotech startup Shattuck Labs raises $118M to fight cancer | Shattuck Labs, a biotech startup co-located in Austin and Durham, N.C., has raised a $118 million Series B investment to continue developing cancer-fighting treatments, the company announced Monday. San Francisco-based health care investmen... |
| 15.06.2020 | Shattuck Labs Closes $118M Series B Financing | Shattuck Labs, Inc., a Durham, North Carolina and Austin, Texas-based clinical-stage biotechnology company advancing its proprietary Agonist Redirected Checkpoint (ARC™) platform to develop a novel class of biologic medicines for the treatm... |